CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity

被引:10
作者
Christensen, Hege [1 ]
Hestad, Anette L. [1 ]
Molden, Espen [1 ]
Mathiesen, Liv [2 ]
机构
[1] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, N-0316 Oslo, Norway
[2] Norwegian Med Agcy, Oslo, Norway
关键词
DRUG-METABOLISM; ESCHERICHIA-COLI; EXPRESSED CYPS; CYP3A4; MICROSOMES; MEMBRANES; B(5);
D O I
10.3109/00498254.2010.523734
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Data from in vitro drug metabolism studies with recombinant enzyme systems are frequently used to predict human drug metabolism in vivo. However, for the CYP3A probe substrate midazolam (MDZ), considerable variability in enzyme kinetic parameters has been observed in different in vitro studies. The aim of this study was to explore the effect of varying activities of the electron donor NADPH-cytochrome P450 reductase (CPR) on CYP3A5-mediated metabolism of MDZ. Microsomes with similar levels of CYP3A5 but 12-fold difference in CPR activity showed a 30-fold difference in intrinsic clearance for the formation of 1'-OH-MDZ. Significantly higher K(m) and lower V(max) for the formation of 1'-OH-MDZ were found in microsomes with low CPR activity compared with microsomes with higher CPR activity (P = 0.024 and 0.001). In the microsomes with lowest CPR activity, the formation of 1'-OH-MDZ displayed Michaelis-Menten kinetics, whereas substrate inhibition was observed in the two preparations with higher CPR activity. The present study shows that the CPR activity in different recombinant enzyme preparations is crucial for in vitro CYP3A5-mediated clearance of MDZ. This suggests that the CPR activity of enzyme preparations could be an important factor for the ability of in vitro data to predict human drug metabolism in vivo.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 13 条
[1]   Different Enzyme Kinetics of Midazolam in Recombinant CYP3A4 Microsomes from Human and Insect Sources [J].
Christensen, Hege ;
Mathiesen, Liv ;
Postvoll, Lillian W. ;
Winther, Bjorn ;
Molden, Espen .
DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (03) :261-268
[2]   Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns [J].
Emoto, C. ;
Iwasaki, K. .
XENOBIOTICA, 2006, 36 (2-3) :219-233
[3]  
Emoto Chie, 2008, Drug Metab Lett, V2, P190, DOI 10.2174/187231208785425737
[4]   Evaluation of microsomal incubation conditions on CYP3A4-mediated metabolism of cyclosporine a by a statistical experimental design [J].
Hermann, M ;
Kase, ET ;
Molden, E ;
Christensen, H .
CURRENT DRUG METABOLISM, 2006, 7 (03) :265-271
[5]  
Houston JB, 2000, DRUG METAB DISPOS, V28, P246
[6]   Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor:: Effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b5 in the expression system and the differences in the marker activities [J].
Nakajima, M ;
Tane, K ;
Nakamura, S ;
Shimada, N ;
Yamazaki, H ;
Yokoi, T .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) :952-963
[7]   Drug metabolism by Escherichia coli expressing human cytochromes P450 [J].
Parikh, A ;
Gillam, EMJ ;
Guengerich, FP .
NATURE BIOTECHNOLOGY, 1997, 15 (08) :784-788
[8]   Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors [J].
Proctor, NJ ;
Tucker, GT ;
Rostami-Hodjegan, A .
XENOBIOTICA, 2004, 34 (02) :151-178
[9]   VALIDATION AND USE OF CLONED, EXPRESSED HUMAN DRUG-METABOLIZING-ENZYMES IN HETEROLOGOUS CELLS FOR ANALYSIS OF DRUG-METABOLISM AND DRUG-DRUG INTERACTIONS [J].
REMMEL, RP ;
BURCHELL, B .
BIOCHEMICAL PHARMACOLOGY, 1993, 46 (04) :559-566
[10]  
Venkatakrishnan K, 2000, DRUG METAB DISPOS, V28, P1493